DNA strand and Cancer Cell Oncology
Market Herald logo


Be the first with the news that moves the market
  • ImpediMed has launched a prevention program to end cancer-related lymphoedema
  • Lymphoedema is when a large amount of fluid accumulates and causes swelling in your body
  • It costs the U.S. healthcare system around $7 billion each year
  • The company’s prevention program is aimed at educating patients and healthcare providers that this condition can be detected and managed early on
  • ImpediMed’s shares are up 6.45 per cent, trading at 16.5 cents apiece

ImpediMed has launched a new, comprehensive Lymphoedema Prevention Program to end cancer-related lymphoedema.

ImpediMed is a world leader in the design and manufacture of medical devices using bioimpedance spectroscopy (BIS) technologies to use when assessing and monitoring tissue composition and fluid status in patients.

Lymphoedema is the accumulation of large amounts of protein-rich fluid, resulting in swelling of one or more regions of the body.

The Lymphoedema Prevention Program utilises the company’s Test, Trigger, Treat protocol for early detection and intervention of the condition.

Currently, one in three at-risk cancer survivors will develop secondary lymphoedema related to their cancer treatment which costs the U.S. healthcare system roughly $7 billion every year.

ImpediMed’s prevention program is aimed at educating patients and healthcare providers that lymphoedema can be detected and managed before it becomes a “debilitating chronic condition.”

“As lymphoedema awareness grows, patients will favour cancer centres and surgical practices that offer effective and comprehensive prevention programs. By working together, we can stop the progression of lymphoedema,” ImpediMed Chief Medical Officer Dr Frank Vicini said.

ImpediMed is at the forefront of lymphoedema prevention. Its FDA-cleared medical device, SOZO is sold in the select market across the world.

The company also has a new website,, which offers easy access to the extensive information about preventing lymphoedema. It includes videos and other educational material for surgeons, cancer centres, caregivers and patients.

ImpediMed’s shares are up 6.45 per cent, trading at 16.5 cents a share as at 4:10 pm AEDT.

IPD by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.